|
|
| Product Name: | FKBP4 antibody | | Synonyms: | FKBP4 antibody;Rabbit Polyclonal FKBP4 Antibody | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![FKBP4 antibody Structure]() |
| | FKBP4 antibody Chemical Properties |
| | FKBP4 antibody Usage And Synthesis |
| Source | Rabbit | | Applications | FKBP4 antibody has been tested by ELISA, Western blot and immunohistochemistry analysis to assure specificity and reactivity. Recommended dilution range for Western blot is 1:1,000 ~ 1:2,000 and immunohistochemistry analysis is 1:50~100. Recommended star | | Reactivity | Human;Mouse;Rat;Hamster;Monkey | | Immunogen | Anti-human FKBP4 mAb is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human FKBP4 amino acids 1-459 purified from E. coli. | | Background | FKBP4 is part of the immunophilin protein family, which takes part in immunoregulation and necessary cellular processes concerning protein folding and trafficking. FKBP4 is a cis-trans prolyl isomerase that connects to the immunosuppressants FK506 and rapamycin. FKBP4 has high structural and functional similarity to FKBP1A, though, FKBP4 does not have immunosuppressant activity when complexed with FK506. FKBP4 interacts with interferon regulatory factor-4 and is involved in immunoregulatory gene expression in B and T lymphocytes. FKBP4 is known to connect with phytanoyl-CoA alpha-hydroxylase. FKBP4 associates with HSP90 & HSP70 thus takes part in the intracellular trafficking of hetero-oligomeric forms of the steroid hormone receptors. FKBP4 highly associates with adeno-associated virus type 2 vectors (AAV) resulting in a considerable increase in AAV-mediated transgene expression in human cell lines. FKBP4 is involved in the optimal use of AAV vectors in human gene therapy. | | References | [1] Peattie, D.A. et al. (1992) Proc Natl Acad Sci U S A 89, 10974-8.
[2] Wu, B. et al. (2004) Proc Natl Acad Sci U S A 101, 8348-53.
[3] De Leon, J.T. et al. (2011) Proc Natl Acad Sci U S A 108, 11878-83.
[4] Ebong, I.O. et al. (2011) Proc Natl Acad Sci U S A 108, 17939-44.
[5] Sivils, J.C. et al. (2011) Curr Opin Pharmacol 11, 314-9.
[6] Chambraud, B. et al. (2010) Proc Natl Acad Sci U S A 107, 2658-63.
[7] Sanokawa-Akakura, R. et al. (2010) PLoS One 5, e8626. |
| | FKBP4 antibody Preparation Products And Raw materials |
|